MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ
4.310
+0.400
+10.23%
After Hours: 4.230 -0.08 -1.86% 18:09 02/06 EST
OPEN
4.160
PREV CLOSE
3.910
HIGH
4.388
LOW
3.850
VOLUME
158.27K
TURNOVER
--
52 WEEK HIGH
91.25
52 WEEK LOW
3.130
MARKET CAP
11.61M
P/E (TTM)
-0.0771
1D
5D
1M
3M
1Y
5Y
1D
Moleculin Biotech Shareholders Approve Warrant Share Issuance
TipRanks · 1d ago
Moleculin Biotech Inc. Held Special Stockholder Meeting
Reuters · 1d ago
Moleculin Biotech Inc. hielt Hauptversammlung ab
Reuters · 1d ago
Moleculin Biotech nimmt an virtueller Corporate-Connect-Konferenz von Webull Financial teil
Reuters · 1d ago
Moleculin Biotech to Present at Webull Financial Corporate Connect Webinar Series
Reuters · 1d ago
Weekly Report: what happened at MBRX last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at MBRX last week (0119-0123)?
Weekly Report · 01/26 10:14
Weekly Report: what happened at MBRX last week (0112-0116)?
Weekly Report · 01/19 10:20
More
About MBRX
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Webull offers Moleculin Biotech Inc stock information, including NASDAQ: MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.